By integrating structural bioinformatics with molecular and expression data, this study aims to reinforce the role of EGFR, ALK, KRAS, and PD-1 as precision targets in lung cancer, providing a foundation for future diagnostics, therapeutic design, and personalized oncology strategies (15). This evidence concerns the gene PDCD1 and lung carcinoma.